IL6 and COVID-19: Intriguingly, Multivariate ANOVA with Bonferroni’s multiple testing revealed the significant reduction in the protein expression level of IL-6 in patients that received COVID-19 treatments (e.g., tocilizumab, lopinavir/ritonavir, favipiravir) in comparison to untreated patients.